Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Oxybutynin: an overview of the available formulations

Authors Rebecca J McCrery, Rodney A Appell

Published 15 March 2006 Volume 2006:2(1) Pages 19—24


Rebecca J McCrery, Rodney A Appell

Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA

Abstract: Overactive bladder (OAB) is a common problem presented to by physicians. Standard treatment with antimuscarinic medication is directed at suppressing involuntary detrusor contractions by blocking the binding of acetylcholine to muscarinic receptors in the bladder. Oxybutynin chloride is the first of several antimuscarinic medications to be marketed for OAB. Although efficacious for treating OAB symptoms, the side effects and suboptimal dosing regimen decrease its utility. To improve patient compliance and tolerability, alternative delivery systems for oxybutynin have subsequently been developed and include a once-daily formulation and a transdermal system. The currently available formulations of oxybutynin are the subject of this review.

 

Keywords: overactive bladder, antimuscarinic, urinary incontinence, detrusor overactivity

Download Article [PDF]